Total marrow radiation using a targeted intensity plan before transplant
Part of Blood & lymphatic, Cancer clinical trials.
This Phase 2 study tests a more precise type of whole bone-marrow radiation before a stem cell transplant. It may help patients with certain high-risk blood cancers by preparing the body for transplant more safely and effectively.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have a planned stem cell transplant using a related half-match (haploidentical) donor or an unrelated donor with an allowed level of mismatch.
- Your diagnosis is one of the study types (such as relapsed/refractory acute leukemia, certain poor-risk AML or ALL in first remission, specific MDS situations, or mixed lineage/biphenotypic leukemia).
- Your heart, liver, and lung tests meet required thresholds (for example, heart pumping ≥40%, liver tests not too high, and lung function above the minimum).
- You must be able to sign informed consent.
- You should not have had more than 20% of the bone-marrow radiation areas previously, and you should not have major health limitations (like very weak heart function or very poor lung function).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests ways to lower the risk of graft-versus-host disease (GVHD), a serious complication after an allogeneic stem cell transplant from a matched donor. It is for people with acute leukemia or MDS who are going to receive intensive conditioning therapy, aiming to improve safety while keeping the transplant effective.
This Phase 2 trial tests whether a specific stem cell transplant method (from a related “half-matched” donor) plus conditioning chemo and radiation can improve outcomes for several blood cancers. It may help people whose cancer is in remission but still considered high risk, or those who have had limited response after prior treatment.
This trial tests a precise type of radiation called intensity modulated total marrow irradiation before a stem cell transplant. It aims to destroy cancer cells while reducing side effects for patients with high-risk leukemia or myelodysplastic syndrome.
This trial is testing a more targeted way to deliver radiation before a stem cell transplant, aiming to reduce side effects while helping the new cells engraft. It includes two different radiation doses, one for first-time transplant patients and another for those who have relapsed after a prior transplant.
This trial tests a new approach: giving a targeted radioactive antibody (attached to a drug that finds CD38 on cancer cells) along with low-dose chemotherapy and targeted radiation to the bone marrow before a donor stem cell transplant. The goal is to prepare the body for the transplant while killing remaining cancer cells more precisely.
This Phase 1 trial tests a special bone marrow transplant using a related “half-matched” donor (haploidentical), without a specific immune-suppressing medicine (“IS-free”). It’s for adults with certain high-risk AML or MDS to see if this approach can improve control of the disease while tracking safety.
Hear when a new Acute Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.